AUR-AFE9-TTM4-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.690
- BILE_ACID_METABOLISM+0.680
- FATTY_ACID_METABOLISM+0.600
- COAGULATION+0.520
- ADIPOGENESIS+0.470
- CHOLESTEROL_HOMEOSTASIS+0.420
- PEROXISOME+0.400
- PANCREAS_BETA_CELLS+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- IL6_JAK_STAT3_SIGNALING+0.340
Top 10 suppressed
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V1-0.600
- MITOTIC_SPINDLE-0.490
- MYC_TARGETS_V2-0.450
- DNA_REPAIR-0.400
- PROTEIN_SECRETION-0.400
- WNT_BETA_CATENIN_SIGNALING-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.270
- PI3K_AKT_MTOR_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088896 | — | — | 0.897 |
| 2 | SRR5088897 | — | — | 0.894 |
| 3 | MBCProject_0217_T2_RNA | — | C | 0.889 |
| 4 | SRR975594 | — | — | 0.888 |
| 5 | SRR11296843 | — | — | 0.866 |
| 6 | d2bd30d9-e0ce-4b80-889b-974bc0563d9c | — | — | 0.839 |
| 7 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.833 |
| 8 | SRR4195657 | — | — | 0.832 |
| 9 | ERR2598280 | fetal | fetal | 0.832 |
| 10 | BS_2R9TCR03 | low-grade glioma | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.690 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.680 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.600 | Inavolisib | — uncovered |
| COAGULATION | 0.520 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.470 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| PEROXISOME | 0.400 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |